iSpecimen Adds New Global Biospecimen Suppliers to Proprietary Marketplace Platform for Researchers to Leverage

Rhea-AI Summary

iSpecimen (Nasdaq: ISPC) announced the addition of new global biospecimen suppliers to its Marketplace, enhancing research capabilities for oncology and cardiovascular disease. The new suppliers include a U.S.-based cancer-focused biobank and a European biobank with extensive health data from participants aged 45 to 75. These biospecimens, including pre- and post-treatment samples, are expected to aid in clinical research for treatments, addressing critical health issues as cancer and cardiovascular diseases remain leading causes of death in the U.S.

Positive

• Addition of new global biospecimen suppliers enhances research capabilities.
• Access to diverse biospecimens supports oncology and cardiovascular research.
• New biobanks provide differentiated pre- and post-treatment data.

Negative

• None.

New Suppliers Will Increase Access to Unique Banked Biospecimens for Advancing Oncology and Cardiovascular Disease Research

LEXINGTON, Mass., July 07, 2022 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists in need of biospecimens for medical research with a network of healthcare specimen providers, announced today that it has added new global biospecimen suppliers to its proprietary Marketplace platform for advancing oncology and cardiovascular disease research.

The new suppliers include a cancer-focused biobank in the United States, which contains a differentiated range of pre- and post-treatment tissue and biofluids across multiple cancer types. These samples provide rich data, including genetic, treatment, follow-up and outcome information. Additionally, iSpecimen has retained a European biobank equipped with a vast urine and blood sample inventory from healthy participants aged 45 to 75, collected with participant health data generated from questionnaires and disease diagnoses. This biobank contains vital early-onset cancer and cardiovascular disease samples, as well.

“As cardiovascular disease and cancer remain the top two leading causes of death in the U.S., respectively, these biospecimens are among the most sought-after samples for medical researchers,” said Christopher Ianelli, MD, Ph.D., iSpecimen Founder and CEO. “Through adding new, distinctive biobanks to the iSpecimen Marketplace, coupled with our recently enhanced technology capabilities, researchers now have access to more coveted biospecimens that can help to expedite clinical research and bring lifesaving treatments to the market sooner for patients in need.”

About iSpecimen
iSpecimen (Nasdaq: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit www.ispecimen.com.

Forward Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are characterized by future or conditional verbs such as “may,” “will,” “expect,” “intend,” “anticipate,” “believe,” “estimate” and “continue” or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information.

Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risk factors contained in the Company’s filings with the Securities and Exchange Commission, which are available for review at www.sec.gov. Forward-looking statements speak only as of the date they are made. New risks and uncertainties arise over time, and it is not possible for the Company to predict those events or how they may affect the Company. If a change to the events and circumstances reflected in the Company’s forward-looking statements occurs, the Company’s business, financial condition and operating results may vary materially from those expressed in the Company’s forward-looking statements.

Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:

Media Contacts
KCSA Strategic Communications
Raquel Cona / Shana Marino
iSpecimen@kcsa.com

Investor Contact
KCSA Strategic Communications
Allison Soss
iSpecimen@kcsa.com

FAQ

What new suppliers did iSpecimen add for biospecimens?

iSpecimen added a cancer-focused biobank in the U.S. and a European biobank for advancing oncology and cardiovascular disease research.

How will the new biospecimens impact research?

The new biospecimens will facilitate clinical research and may expedite the development of lifesaving treatments for cancer and cardiovascular diseases.

What types of samples are included in the new biobanks?

The new biobanks include pre- and post-treatment tissue, biofluids, urine, and blood samples along with participant health data.